Radiotherapy Department, Istituto del Radio "O. Alberti", Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy,
Radiol Med. 2013 Oct;118(7):1220-39. doi: 10.1007/s11547-013-0925-z. Epub 2013 May 27.
Radiotherapy (RT) has an established role in the treatment of prostate cancer patients. Despite the large number of patients treated with RT, some issues about optimal techniques, doses, volumes, timing, and association with androgen deprivation are still subject of debate. The aim of this survey was to determine the patterns of choice of Italian radiation oncologists in two different clinical cases of prostate cancer patients treated with radical RT.
During the 2010 Italian Association of Radiation Oncology (AIRO) National congress, four different clinical cases were presented to attending radiation oncologists. Two of them were prostate cancer cases that could be treated by RT +/- hormonal therapy (HT), different for T stage of primary tumour according to TNM, preoperative diagnostic procedures for staging, initial prostate specific antigen (iPSA), and Gleason Score sum of biopsy. For each clinical case, radiation oncologists were asked to: (a) give indication to pretreatment procedures for staging; (b) give indication to treatment; (c) define specifically, where indicated, total dose, type of fractionation, volumes of treatment, type of technique, type of image-guided setup control; (d) indicate if HT should be prescribed; (e) define criteria that particularly influenced prescription. A descriptive statistical analysis was performed.
Three hundred questionnaires were given to radiation oncologists attending the congress, 128 questionnaires were completed and considered for this analysis (41%). Some important differences were shown in prescribing and delivering RT, particularly with regards to treatment volumes and fractionation.
Despite the results of clinical trials, several differences still exist among Italian radiation oncologists in the treatment of prostate cancer patients. These patients probably deserve a more uniform approach, based on upto-date, detailed, and evidence-based recommendations.
放射治疗(RT)在前列腺癌患者的治疗中具有明确的作用。尽管有大量的患者接受 RT 治疗,但在优化技术、剂量、体积、时间以及与雄激素剥夺的关联等方面仍存在一些争议。本研究旨在确定意大利放射肿瘤学家在两种不同的前列腺癌患者根治性 RT 治疗方案中的选择模式。
在 2010 年意大利放射肿瘤学会(AIRO)全国大会期间,向与会的放射肿瘤学家展示了四个不同的临床病例。其中两个是前列腺癌病例,可以通过 RT +/- 激素治疗(HT)进行治疗,根据 TNM 原发性肿瘤的 T 分期、术前分期诊断程序、初始前列腺特异性抗原(iPSA)和活检的 Gleason 评分总和不同。对于每个临床病例,放射肿瘤学家被要求:(a)给出分期前预处理的指征;(b)给出治疗的指征;(c)在需要时具体定义总剂量、分割类型、治疗体积、技术类型、图像引导设置控制类型;(d)指示是否应开具 HT 处方;(e)定义特别影响处方的标准。进行了描述性统计分析。
向参加大会的放射肿瘤学家发放了 300 份问卷,有 128 份问卷完成并纳入本分析(41%)。在开具和提供 RT 方面显示出一些重要的差异,特别是在治疗体积和分割方面。
尽管临床试验的结果如此,但意大利放射肿瘤学家在治疗前列腺癌患者方面仍存在一些差异。这些患者可能需要一种更统一的方法,基于最新的、详细的、基于证据的建议。